Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Patients With Definitely EGFR T790M State Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an EGFR TKI Agent
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2017
At a glance
- Drugs Avitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Hangzhou ACEA Pharmaceutical Research
- 26 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 Oct 2017.
- 06 Jun 2017 Results (n=16) assessing safety, the intracranial/extracranial efficacy, and the blood brain barrier (BBB) penetration rate of Avitinib, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 06 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 May 2017.